View the latest news and SEC filings
Scroll to
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Initial filing by director officer or owner of more than ten percent. |
3 |
3,4,5 |
|
|
January 4, 2021 |
Form of prospectus reflecting facts events constituting substantive change from last form |
424B3 |
Registration Statements |
|
|
December 30, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
November 24, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
